Advanz Adds Biosimilars Alliance With Alkem’s Enzene
Firms Strike Exclusive Partnership To Develop And Commercialize Rare Disease Drug
Executive Summary
Advanz Pharma has further built out its biosimilars interests by striking a deal with Alkem’s Enzene Biosciences subsidiary to develop and commercialize a rare disease treatment.